BMY · Bristol-Myers Squibb Co.

The thesis

Bristol Myers Squibb has stacked up more positive late-stage trial results since the last note, yet the shares have not moved. They closed at $60.57 on 28 October 2026, 10.1% below the 52-week high of $67.39 (adjusted daily closes). The third-quarter report, scheduled for 8:00 a.m. Eastern on 29 October 2026, decides whether the July guidance of $49–50 billion in 2026 revenue and $6.75–7.00 in adjusted earnings per share holds.

The narrative is maturing: the July guidance raise and the October trial readouts are all public, and the shares have fallen 6.3% over three months. The 14-day Relative Strength Index (a 0–100 gauge of recent buying versus selling) reads 53.0, up from 44.1 in the previous note. That close matches the $60.57 close cited on 15 October 2026, so two weeks of new data produced no net price change. The rating stays low: the pipeline evidence is good, but the shares have not confirmed it and the report lands the same day this note is dated.

Bullish and bearish views on Bristol-Myers Squibb Co.

The bull case on Bristol-Myers Squibb Co. (BMY), in brief: Guidance reset rests on reported results. The bear case: Good news met selling.

Bull case

• Guidance reset rests on reported results. On 30 July 2026 the company reported second-quarter revenue of $12.973 billion and adjusted earnings of $2.04 per share, against estimates of $11.745 billion and $1.59 (Benzinga). It raised 2026 revenue guidance from $46.0–47.5 billion to $49.0–50.0 billion.
• Lung cancer drug hits its main goal. On 26 October 2026 Bristol Myers and SystImmune said the Phase 3 PANKU-Lung01 trial of izalontamab brengitecan met its primary endpoint at an interim analysis. Median progression-free survival was 11.1 months versus 5.7 months, a hazard ratio of 0.40 (company news via Benzinga).
• Same drug works in breast cancer. On 23 October 2026 the companies reported that the PANKU-Breast01 interim analysis showed a 59% lower risk of progression or death versus chemotherapy.
• Second lung cancer drug shows activity. At the ESMO cancer congress on 25 October 2026, BioNTech and Bristol Myers reported a 36.7% confirmed objective response rate for pumitamig plus docetaxel in a Phase 2 lung cancer trial (ROSETTA Lung-107). A Phase 3 trial of pumitamig began on 22 October 2026.
• Lung fibrosis and myeloma wins earlier in October. On 12 October 2026 the Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint at 60 mg. On 8 October 2026 a Zenbexus combination cut the risk of myeloma progression or death by 51% in a Phase 3 trial.
• Some analysts stay constructive. Piper Sandler kept Overweight on 26 October 2026 and lowered its target to $78. Guggenheim's target is $75 and JPMorgan's is $73 (Benzinga, 31 July 2026).

Bear case

• Good news met selling. Per BioPharma Dive, the shares rose more than 6% before the 12 October 2026 open on the admilparant result, then reversed to a loss of about 4% that morning. The 120 mg dose missed statistical significance, and the company has not disclosed effect sizes.
• A safety question on the autoimmune program. On 23 October 2026 the company presented interim Phase 1 multiple sclerosis data for zola-cel, a cell therapy. A company spokesperson said a Grade 5 event, the trial grading for a death, disclosed with the data occurred after the trial pause, and that the company is working closely with the FDA.
• Targets sit on both sides of the price. Wells Fargo lowered its target to $60 on 13 October 2026, Cantor Fitzgerald cut to $53 on 8 October 2026, and Leerink Partners downgraded to Market Perform with a $59 target on 5 October 2026. Morgan Stanley kept Underweight with a $41 target on 7 October 2026, and Goldman Sachs maintained Hold on 20 October 2026.
• Consensus is not bullish. Benzinga's page, updated 4 September 2026, showed a $62 average target across 24 analysts, with 10 Buy, 13 Hold and 1 Sell ratings.
• The shares lag despite the data. The three-month decline of 6.3% to 28 October 2026 comes after the company raised guidance and reported five positive trial results in October.

Price setup

The last adjusted close was $60.57 on 28 October 2026. The 52-week high is $67.39, so the shares sit 10.1% below it. The $63 level from the earlier note has not been regained.

The nearest reference points are analyst targets, which cluster around the price: Leerink Partners at $59, Wells Fargo at $60, and the Benzinga average of $62 as of 4 September 2026. A daily close below $58 would put the shares under every one of those marks except Cantor Fitzgerald's $53 and Morgan Stanley's $41.

Crowding evidence is limited. The report falls on 29 October 2026, so the earnings date is immediate. SEC Form 4 insider filings and retail-attention data were not checked, and no share issuance is reported. The spread of analyst targets, from $41 to $78, shows professionals disagree rather than agree.

Catalysts, next 30 days

• Undated: zola-cel regulatory update. The company has said it is working with the FDA, and no formal clinical hold has been announced.

Elapsed catalysts

• 29 October 2026: Third-quarter 2026 results. The call starts at 8:00 a.m. Eastern. Results had not been published in the sources checked when this note was written. (passed 8d ago)
• 2 November 2026: Quarterly dividend of $0.63 per share. Payable to holders of record on 2 October 2026, as declared by the company. (passed 4d ago)
• After 29 October 2026: analyst target revisions. Targets are clustered near the price, so the report is likely to move several of them. (passed 8d ago)

What would change the view

A cut to the $49–50 billion revenue guidance or the $6.75–7.00 adjusted earnings guidance on 29 October 2026 would break the case, since the July raise is the main support for the shares. A formal FDA clinical hold or termination of the zola-cel autoimmune program would also break it. On price, a daily close below $58 would put the shares below the Leerink Partners and Wells Fargo targets and show that the October trial wins have not changed how the market values the company.

The case strengthens if guidance holds or rises and the shares close above the $63 level from the previous note. It strengthens further if the shares recover toward the $67.39 52-week high. Detailed admilparant effect sizes that show a clear benefit at 60 mg would also help.

What it trades with

Bristol Myers trades as a large-cap pharmaceutical company in the middle of a product-cycle transition. Its moves follow its own pipeline news and the sector's response to drug-pricing policy more than the AI-led market leaders. Eliquis is in the first CMS Medicare price-negotiation cohort, with negotiated prices effective 1 January 2026.

The 2 August 2026 report of an AstraZeneca merger was denied on 5 August 2026, and later press on a combination has no filing or company statement behind it. BioNTech and SystImmune are partners on the pumitamig and izalontamab brengitecan programs, so their trial news bears directly on the same assets.